Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Multiple Sclerosis

  Free Subscription


Articles published in J Neurol Neurosurg Psychiatry

Retrieve available abstracts of 41 articles:
HTML format
Text format



Single Articles


    September 2018
  1. PALACE J, Duddy M, Lawton M, Bregenzer T, et al
    Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme.
    J Neurol Neurosurg Psychiatry. 2018 Sep 21. pii: jnnp-2018-318360.
    PubMed     Text format     Abstract available


  2. KOUTSIS G, Breza M, Velonakis G, Tzartos J, et al
    X linked Charcot-Marie-Tooth disease and multiple sclerosis: emerging evidence for an association.
    J Neurol Neurosurg Psychiatry. 2018 Sep 8. pii: jnnp-2018-319014.
    PubMed     Text format     Abstract available


    July 2018
  3. JACOBS BM, Ammoscato F, Giovannoni G, Baker D, et al
    Cladribine: mechanisms and mysteries in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Jul 10. pii: jnnp-2017-317411.
    PubMed     Text format     Abstract available


  4. LANDI D, Ragonese P, Prosperini L, Nociti V, et al
    Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Jul 3. pii: jnnp-2018-318468.
    PubMed     Text format     Abstract available


    June 2018
  5. CHEN J, Taylor BV, Blizzard L, Simpson S Jr, et al
    Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
    J Neurol Neurosurg Psychiatry. 2018 Jun 19. pii: jnnp-2018-318228.
    PubMed     Text format     Abstract available


    May 2018
  6. TAYLOR BV
    Search for a prognostic biomarker in multiple sclerosis: a step in the right direction?
    J Neurol Neurosurg Psychiatry. 2018 May 15. pii: jnnp-2018-318326.
    PubMed     Text format    


  7. RATHBONE E, Durant L, Kinsella J, Parker AR, et al
    Cerebrospinal fluid immunoglobulin light chain ratios predict disease progression in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 May 9. pii: jnnp-2018-317947.
    PubMed     Text format     Abstract available


    April 2018
  8. CERQUEIRA JJ, Compston DAS, Geraldes R, Rosa MM, et al
    Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?
    J Neurol Neurosurg Psychiatry. 2018 Apr 4. pii: jnnp-2017-317509.
    PubMed     Text format    


    March 2018
  9. WIJNANDS JMA, Zhu F, Kingwell E, Fisk JD, et al
    Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
    J Neurol Neurosurg Psychiatry. 2018 Mar 30. pii: jnnp-2017-317493.
    PubMed     Text format     Abstract available


  10. POTTGEN J, Moss-Morris R, Wendebourg JM, Feddersen L, et al
    Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Mar 16. pii: jnnp-2017-317463.
    PubMed     Text format     Abstract available


    December 2017
  11. PATTI F
    Standardised Frankincense extract: new possible therapeutic option for patients with relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Dec 23. pii: jnnp-2017-317380.
    PubMed     Text format    


  12. STURNER KH, Stellmann JP, Dorr J, Paul F, et al
    A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial).
    J Neurol Neurosurg Psychiatry. 2017 Dec 16. pii: jnnp-2017-317101.
    PubMed     Text format     Abstract available


  13. COCOZZA S, Petracca M, Mormina E, Buyukturkoglu K, et al
    Cerebellar lobule atrophy and disability in progressive MS.
    J Neurol Neurosurg Psychiatry. 2017;88:1065-1072.
    PubMed     Text format     Abstract available


    October 2017
  14. AZARY S, Schreiner T, Graves J, Waldman A, et al
    Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Oct 9. pii: jnnp-2017-315936.
    PubMed     Text format     Abstract available


  15. FITZGERALD K
    Diet and disease modification in multiple sclerosis: a nutritional epidemiology perspective.
    J Neurol Neurosurg Psychiatry. 2017 Oct 9. pii: jnnp-2017-316375.
    PubMed     Text format    


  16. MEIJER KA, Eijlers AJC, Geurts JJG, Schoonheim MM, et al
    Staging of cortical and deep grey matter functional connectivity changes in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Oct 6. pii: jnnp-2017-316329.
    PubMed     Text format     Abstract available


    September 2017
  17. GAJOFATTO A, Nourbakhsh B, Benedetti MD, Waubant E, et al
    Performance of 2010 McDonald criteria and 2016 MAGNIMS guidelines in the diagnosis of primary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Sep 22. pii: jnnp-2017-316911.
    PubMed     Text format    


  18. PATERGNANI S, Castellazzi M, Bonora M, Marchi S, et al
    Autophagy and mitophagy elements are increased in body fluids of multiple sclerosis-affected individuals.
    J Neurol Neurosurg Psychiatry. 2017 Sep 2. pii: jnnp-2017-316234.
    PubMed     Text format    


    August 2017
  19. SPENCER JI, Bell JS, DeLuca GC
    Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier.
    J Neurol Neurosurg Psychiatry. 2017 Aug 31. pii: jnnp-2017-316011.
    PubMed     Text format     Abstract available


  20. CALABRESE M, Pitteri M, Farina G, Bajrami A, et al
    Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events.
    J Neurol Neurosurg Psychiatry. 2017 Aug 26. pii: jnnp-2017-316236.
    PubMed     Text format     Abstract available


  21. CLAFLIN SB, van der Mei IAF, Taylor BV
    Complementary and alternative treatments of multiple sclerosis: a review of the evidence from 2001 to 2016.
    J Neurol Neurosurg Psychiatry. 2017 Aug 2. pii: jnnp-2016-314490.
    PubMed     Text format     Abstract available


  22. KOCH-HENRIKSEN N, Laursen B, Stenager E, Magyari M, et al
    Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study.
    J Neurol Neurosurg Psychiatry. 2017;88:626-631.
    PubMed     Text format     Abstract available


  23. GRYTTEN N
    Survival in multiple sclerosis: things have changed.
    J Neurol Neurosurg Psychiatry. 2017;88:618.
    PubMed     Text format    


  24. LASCANO AM, Lalive PH, Hardmeier M, Fuhr P, et al
    Clinical evoked potentials in neurology: a review of techniques and indications.
    J Neurol Neurosurg Psychiatry. 2017;88:688-696.
    PubMed     Text format     Abstract available


    July 2017
  25. ZHOU Y, Graves JS, Simpson S Jr, Charlesworth JC, et al
    Genetic variation in the gene LRP2 increases relapse risk in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Jul 24. pii: jnnp-2017-315971.
    PubMed     Text format     Abstract available


  26. PREZIOSA P, Rocca MA, Mesaros S, Meani A, et al
    Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria.
    J Neurol Neurosurg Psychiatry. 2017 Jul 19. pii: jnnp-2017-315863.
    PubMed     Text format    


  27. EISELE P, Szabo K, Alonso A, Ong M, et al
    Lack of T1 hyperintensity in the dentate nucleus after 15 administrations of a macrocyclic contrast agent in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Jul 14. pii: jnnp-2017-316102.
    PubMed     Text format    


    May 2017
  28. TETTEY P, Simpson S, Taylor B, Ponsonby AL, et al
    An adverse lipid profile and increased levels of adiposity significantly predict clinical course after a first demyelinating event.
    J Neurol Neurosurg Psychiatry. 2017;88:395-401.
    PubMed     Text format     Abstract available


    April 2017
  29. RAGONESE P
    Mortality studies for multiple sclerosis: still a useful tool to analyse long-term outcome.
    J Neurol Neurosurg Psychiatry. 2017 Apr 28. pii: jnnp-2017-315591.
    PubMed     Text format    


  30. OKADA K, Kobata M, Sennari Y, Iwanaka Y, et al
    Levels of nitric oxide metabolites in cerebrospinal fluid correlate with cognitive impairment in early stage multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Apr 26. pii: jnnp-2017-315585.
    PubMed     Text format    


  31. LUNDE HB, Assmus J, Kjell-Morten M, Bo L, et al
    Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study.
    J Neurol Neurosurg Psychiatry. 2017 Apr 1. pii: jnnp-2016-315238.
    PubMed     Text format     Abstract available


  32. COMI G, De Stefano N, Freedman MS, Barkhof F, et al
    Subcutaneous interferon beta-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study.
    J Neurol Neurosurg Psychiatry. 2017;88:285-294.
    PubMed     Text format     Abstract available


    March 2017
  33. MURPHY R, O'Donoghue S, Counihan T, McDonald C, et al
    Neuropsychiatric syndromes of multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Mar 11. pii: jnnp-2016-315367.
    PubMed     Text format     Abstract available


  34. ZALEWSKI NL, Morris PP, Weinshenker BG, Lucchinetti CF, et al
    Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders.
    J Neurol Neurosurg Psychiatry. 2017;88:218-225.
    PubMed     Text format     Abstract available


    February 2017
  35. JURYNCZYK M, Tackley G, Kong Y, Geraldes R, et al
    Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.
    J Neurol Neurosurg Psychiatry. 2017;88:132-136.
    PubMed     Text format     Abstract available


    December 2016
  36. ROCCA MA, Filippi M
    Modulation of cortical excitability to normalise brain function and improve cognition in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Dec 30. pii: jnnp-2016-315195.
    PubMed     Text format    


  37. HULST HE, Goldschmidt T, Nitsche MA, de Wit SJ, et al
    rTMS affects working memory performance, brain activation and functional connectivity in patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Dec 14. pii: jnnp-2016-314224.
    PubMed     Text format     Abstract available


    November 2016
  38. TAO C, Simpson S Jr, van der Mei I, Blizzard L, et al
    Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Nov 3. pii: jnnp-2016-314013.
    PubMed     Text format     Abstract available


    October 2016
  39. MOROSO A, Ruet A, Lamargue-Hamel D, Munsch F, et al
    Posterior lobules of the cerebellum and information processing speed at various stages of multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Oct 27. pii: jnnp-2016-313867.
    PubMed     Text format     Abstract available


    September 2016
  40. LIZAK N, Lugaresi A, Alroughani R, Lechner-Scott J, et al
    Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Sep 28. pii: jnnp-2016-313976.
    PubMed     Text format     Abstract available


  41. KAWACHI I, Lassmann H
    Neurodegeneration in multiple sclerosis and neuromyelitis optica.
    J Neurol Neurosurg Psychiatry. 2016 Sep 26. pii: jnnp-2016-313300.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: